MediciNova Inc MNOV.OQ MNOV.O is expected to show no change in quarterly revenue when it reports results on February 13 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for MediciNova Inc is for a loss of 5 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for MediciNova Inc is $9.00, above its last closing price of $1.87.
This summary was machine generated February 11 at 21:23 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)